Skip to main content

Gilead Sciences Value Stock - Dividend - Research Selection

Gilead Sciences

ISIN: US3755581036, WKN: 885823

Market price date: 16.05.2022
Market price: 62,24 USD

Gilead Sciences Fundamental data and company key figures of the share

Annual reports in USD
Key figures 26-02-2022
Cash flow
Net operating cash flow 11.384.000.000
Capital Expenditures -579.000.000
Free cash flow 10.805.000.192
Balance sheet
Total Equity
Liabilities & Shareholders equity 67.952.000.000
Income statement
Net income
Eps (diluted) 4,930
Diluted shares outstanding
Net sales/revenue 27.305.000.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C 6,90
P/FC 7,27
Balance sheet
Income statement
Div. Yield4,56%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization78.546.878.464,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-01-28,2.0000/1.0000; 2007-06-25,2.0000/1.0000; 2004-09-07,2.0000/1.0000; 2002-03-08,2.0000/1.0000; 2001-02-22,2.0000/1.0000

Description of the company

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

FOSTER CITY, Calif., May 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical

IN BRIEF: US FDA lifts clinical hold on Gilead's lenacapavir studies

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Top 5 1st Quarter Trades of Cadence Bank




This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield


Large Cap Biopharmaceuticals: Provide Growth, Value And Yield


Stocks Are Undervalued


Stock rebound uncertain for U.S. biotechs as risks multiply for investors

U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.